![](https://alentis.ch/wp-content/uploads/2022/03/a-white.png)
THE CLAUDIN-1 COMPANY
Treat cancer and reverse fibrosis
We are a clinical-stage biotech company with a mission to treat cancer and reverse fibrosis. To this end, we are rapidly advancing our pipeline of anti-Claudin-1 monoclonal antibodies and antibody-drug conjugates (ADCs).
Our team is committed to unlocking the broad potential of our therapeutic target Claudin-1 and bringing new treatments to those in need.
Transformative Claudin-1 antibodies
We are the world leader in developing anti-Claudin-1 treatment. Our first-in-class antibodies specifically target exposed Claudin-1 to open the stiff extracellular matrix, block disease signaling, and in cancer, selectively kill tumor cells.
R&D pipeline
We have developed a promising pipeline of anti-Claudin-1 antibodies. Our two clinical candidates are in Phase 1/2 for solid tumors and Phase 2 for organ fibrosis, respectively. Beyond conventional therapies, our preclinical programs feature anti-Claudin-1 antibody-drug conjugates (ADCs), bispecific antibodies, and T-cell engagers.
Inspired leadership
Our carefully chosen team values collaboration, hard work and shares the belief that anti-Claudin-1 therapies will make a difference for patients. Our highly experienced leadership team is supported by a Board of Directors and a Scientific Advisory Board made up of industry veterans, entrepreneurs and esteemed scientists.
Alentis news
May 14, 2024
ALENTIS ANNOUNCES PRESENTATIONS AT THE ERA AND ATS CONFERENCES
January 08, 2024
WILLIAM PAO JOINS ALENTIS THERAPEUTICS AS INDEPENDENT BOARD MEMBER